WO2008109757A3 - Methods and compositions involving polymeric immunoglobulin fusion proteins - Google Patents

Methods and compositions involving polymeric immunoglobulin fusion proteins Download PDF

Info

Publication number
WO2008109757A3
WO2008109757A3 PCT/US2008/056066 US2008056066W WO2008109757A3 WO 2008109757 A3 WO2008109757 A3 WO 2008109757A3 US 2008056066 W US2008056066 W US 2008056066W WO 2008109757 A3 WO2008109757 A3 WO 2008109757A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
fusion proteins
immunoglobulin fusion
compositions involving
polymeric immunoglobulin
Prior art date
Application number
PCT/US2008/056066
Other languages
French (fr)
Other versions
WO2008109757A2 (en
Inventor
Barry G Arnason
Mark A Jensen
David M White
Original Assignee
Iterative Therapeutics Inc
Barry G Arnason
Mark A Jensen
David M White
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Iterative Therapeutics Inc, Barry G Arnason, Mark A Jensen, David M White filed Critical Iterative Therapeutics Inc
Priority to CA002679743A priority Critical patent/CA2679743A1/en
Priority to EP08731555A priority patent/EP2164859A4/en
Publication of WO2008109757A2 publication Critical patent/WO2008109757A2/en
Publication of WO2008109757A3 publication Critical patent/WO2008109757A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A61K39/001112—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001104—Epidermal growth factor receptors [EGFR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001103—Receptors for growth factors
    • A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/00117—Mucins, e.g. MUC-1
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001169—Tumor associated carbohydrates
    • A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001174—Proteoglycans, e.g. glypican, brevican or CSPG4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00118—Cancer antigens from embryonic or fetal origin
    • A61K39/001182—Carcinoembryonic antigen [CEA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00119—Melanoma antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001193—Prostate associated antigens e.g. Prostate stem cell antigen [PSCA]; Prostate carcinoma tumor antigen [PCTA]; PAP or PSGR
    • A61K39/001194—Prostate specific antigen [PSA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6056—Antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Abstract

The present invention concerns inventive polypeptides. The present invention also concerns compositions and vaccines comprising the inventive polypeptides. In other embodiments of the invention, the inventive polypeptides are provided to a subject, used to vaccinate, or used to induce immunity. Other embodiments include methods for making the inventive polypeptides and nucleic acids used to encode the inventive polypeptides.
PCT/US2008/056066 2007-03-06 2008-03-06 Methods and compositions involving polymeric immunoglobulin fusion proteins WO2008109757A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CA002679743A CA2679743A1 (en) 2007-03-06 2008-03-06 Methods and compositions involving polymeric immunoglobulin fusion proteins
EP08731555A EP2164859A4 (en) 2007-03-06 2008-03-06 Methods and compositions involving polymeric immunoglobulin fusion proteins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89331807P 2007-03-06 2007-03-06
US60/893,318 2007-03-06

Publications (2)

Publication Number Publication Date
WO2008109757A2 WO2008109757A2 (en) 2008-09-12
WO2008109757A3 true WO2008109757A3 (en) 2008-12-24

Family

ID=39739113

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/056066 WO2008109757A2 (en) 2007-03-06 2008-03-06 Methods and compositions involving polymeric immunoglobulin fusion proteins

Country Status (3)

Country Link
EP (1) EP2164859A4 (en)
CA (1) CA2679743A1 (en)
WO (1) WO2008109757A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2172211T3 (en) 2008-10-01 2015-02-16 Immatics Biotechnologies Gmbh Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers
WO2013095973A1 (en) 2011-12-19 2013-06-27 The Rockefeller University Hdc-sign binding peptides
WO2017096221A1 (en) * 2015-12-02 2017-06-08 The Rockefeller University Bispecific anti-hiv broadly neutralizing antibodies
CN112543644A (en) * 2018-07-24 2021-03-23 古德T细胞有限公司 A composition for preventing and treating immune related diseases
WO2020110154A1 (en) * 2018-11-30 2020-06-04 Bharat Biotech International Limited A chimeric therapeutic vaccine

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1395605B8 (en) * 2001-03-09 2014-12-17 Iterative Therapeutics, Inc. Polymeric immunoglobulin fusion proteins that target low-affinity fcgamma receptors

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DUAN ET AL.: "Antitumor activities of TEM8-Fc: an engineered antibody-like molecule targeting tumor endothelial marker 8", J. NATL. CANCER INST., vol. 99, no. 20, 17 October 2007 (2007-10-17), pages 1551 - 1555, XP008126478 *
HEIJNEN ET AL.: "Antigen targeting to myeloid-specific human Fc gamma RI/CD64 triggers enhanced antibody responses in transgenic mice", J OPIN INVEST., vol. 97, no. 2, 15 January 1996 (1996-01-15), pages 331 - 338, XP002345168 *
JENSEN ET AL.: "A novel Fc gamma receptor ligand augments humoral responses by targeting antigen to Fc gamma receptors", EUR. J. IMMUNOL., vol. 37, no. 4, April 2007 (2007-04-01), pages 1139 - 1148, XP008126476 *
WERNERSSON ET AL.: "IgG-mediated enhancement of antibody responses is low in Fc receptor gamma chain-deficient mice and increased in Fc gamma RII-deficient mice", J. IMMUNOL., vol. 163, no. 2, 15 July 1999 (1999-07-15), pages 618 - 622, XP008126477 *
WHITE ET AL.: "Design and expression of polymeric immunoglobulin fusion proteins: a strategy for targeting low-affinity Fcgamma receptors", PROTEIN EXPR. PURIF., vol. 3, 21 April 2001 (2001-04-21), pages 446 - 455, XP008126475 *

Also Published As

Publication number Publication date
EP2164859A2 (en) 2010-03-24
CA2679743A1 (en) 2008-09-12
WO2008109757A2 (en) 2008-09-12
EP2164859A4 (en) 2012-06-06

Similar Documents

Publication Publication Date Title
WO2011008974A3 (en) Rsv f protein compositions and methods for making same
IL195191A (en) Fusion proteins, nucleic acids encoding same and processes for producing same
WO2008114149A3 (en) Respiratory syncytial virus (rsv) chimeric polypeptide comprising the g protein central region domain located in between the f2 and f1 fusion protein domains
EP2037737A4 (en) Proteins, nucleic acids encoding the same and associated methods of use
IL200808A0 (en) Soluble il-17ra/rc fusion proteins and related methods
HK1219490A1 (en) Immunoglobulin fusion proteins
WO2010120514A3 (en) Antigen-binding proteins comprising recombinant protein scaffolds
WO2008145401A3 (en) Mutated parvovirus structural proteins as vaccines
IL218296A0 (en) Obpgplys/endolysin polypeptides, fusion proteins and compositions compriisng the same and uses thereof
IL210485A (en) Isolated antibody or a functional protein, process for its preparation, pharmaceutical composition comprising the same and isolated nucleic acid encoding said antibody or functional protein
WO2011146891A3 (en) High-affinity fully functional soluble single-domain human cd4, antibodies, and related fusion proteins
WO2007133835A8 (en) Ras mutation and compositions and methods related thereto
MX300732B (en) Cellulases, nucleic acids encoding them and methods for making and using them.
EP1892547A4 (en) Heating reinforcing device, fusion connecting device including the heating reinforcing device, and fusion connecting method
WO2007042289A3 (en) Nanobodies™ and polypeptides against egfr and igf-ir
ZA201405521B (en) Plant co2 sensors,nucleic acids encoding them ,and methods for making and using them
EP2089053A4 (en) Hpv antigen fusion protein vaccine compositions and uses thereof
WO2007095350A3 (en) Compositions and methods for use of pigment epithelial derived factor (pedf) peptide fragments
EP1934372A4 (en) Ssb - polymerase fusion proteins
WO2008083271A3 (en) Methods and compositions for enhanced protein expression and purification
EP2144924A4 (en) Fusion protein vaccine
IL169804A (en) 254p1d6b proteins, nucleic acids encoding the same, processes for producing the same, antibodies binding thereto and uses thereof
WO2008109757A3 (en) Methods and compositions involving polymeric immunoglobulin fusion proteins
WO2012054929A3 (en) Use of human serum albumin to decrease antigenicity of therapeutic proteins
WO2010014922A3 (en) Protein purification tags and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08731555

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2679743

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2008731555

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: DE